Renaissance Technologies LLC Sells 59,400 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Renaissance Technologies cut its Structure Therapeutics stake by 51.6% in the first quarter, selling 59,400 shares and retaining 55,800 shares valued at approximately $2.69 million.
• Institutional investors own 91.78% of GPCR, while several funds—including CWM, Assetmark, and others—also adjusted or initiated positions.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and average price target of $110.91, although Structure Therapeutics recently missed quarterly EPS estimates and GPCR opened at $53.14.

Renaissance Technologies LLC cut its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 51.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,800 shares of the company's stock after selling 59,400 shares during the period. Renaissance Technologies LLC owned 0.08% of Structure Therapeutics worth $2,690,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. CWM LLC lifted its position in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company's stock worth $33,000 after acquiring an additional 125 shares in the last quarter. Sterling Capital Management LLC purchased a new stake in Structure Therapeutics during the 1st quarter worth about $28,000. State of Wyoming bought a new position in Structure Therapeutics in the 2nd quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey bought a new position in Structure Therapeutics in the 4th quarter worth about $127,000. Finally, Assetmark Inc. grew its holdings in Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company's stock valued at $123,000 after buying an additional 449 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GPCR shares. Citigroup reaffirmed a "market outperform" rating on shares of Structure Therapeutics in a report on Friday. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research note on Friday. Wall Street Zen lowered Structure Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday. HC Wainwright dropped their price target on Structure Therapeutics from $100.00 to $70.00 and set a "buy" rating for the company in a research report on Thursday, June 11th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $110.91.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $53.14 on Monday. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -53.14 and a beta of -1.43. The business has a 50 day moving average of $47.63 and a 200 day moving average of $53.95. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $15.86 and a 1-year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). As a group, sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source